Latest pharmacotherapy options for benign prostatic hyperplasia

Bibliography

• Issa MM, Fenter TC, Black L, et al. An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. Am J Manag Care 2006;12:S83-9
   Web of Science ®Google Scholar
• Parsons JK. Commentary on BPH and public health – have we lost the forest through the trees? J Urol 2008;179:S81
   Google Scholar
• Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006;49:651-8
   PubMed Web of Science ®Google Scholar
• Roosen A, Chapple CR, Dmochowski RR, et al. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol 2009;56:810-19
   PubMed Web of Science ®Google Scholar
• Emberton M, Cornel EB, Bassi PF, et al. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int J Clin Pract 2008;62:1076-86
   PubMed Web of Science ®Google Scholar
• Abrams P. Re: update on AUA guideline on the management of benign prostatic hyperplasia: K. T. McVary, C. G. Roehrborn, A. L. Avins, M. J. Barry, R. C. Bruskewitz, R. F. Donnell, H. E. Foster, Jr., C. M. Gonzalez, S. A. Kaplan, D. F. Penson, J. C. Ulchaker and J. T. Wei J Urol 2011; 185: 1793-1803. J Urol 2012;187:358-9; author reply 9
   PubMedGoogle Scholar
• Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013;64:118-40
   PubMed Web of Science ®Google Scholar
• Otsuki H, Kosaka T, Nakamura K, et al. Beta3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men. Int Urol Nephrol 2013;45:53-60
   PubMed Web of Science ®Google Scholar
• Hedlund H, Andersson KE, Larsson B. Alpha-adrenoceptors and muscarinic receptors in the isolated human prostate. J Urol 1985;134:1291-8
   PubMed Web of Science ®Google Scholar
• Noguchi Y, Ohtake A, Suzuki M, et al. In vivo study on the effects of alpha1-adrenoceptor antagonists on intraurethral pressure in the prostatic urethra and intraluminal pressure in the vas deferens in male dogs. Eur J Pharmacol 2008;580:256-61
   PubMed Web of Science ®Google Scholar
• Lepor H, Gup DI, Baumann M, et al. Comparison of alpha 1 adrenoceptors in the prostate capsule of men with symptomatic and asymptomatic benign prostatic hyperplasia. Br J Urol 1991;67:493-8
   PubMedGoogle Scholar
• Andersson KE. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol 2002;19:390-6
   Web of Science ®Google Scholar
• Nasu K, Moriyama N, Kawabe K, et al. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol 1996;119:797-803
   PubMed Web of Science ®Google Scholar
• Martin DJ, Angel I, Arbilla S. Functional uroselectivity. Eur Urol 1998;33(Suppl 2):12-18
   Google Scholar
• Warde N. BHP: silodosin an effective new drug for BPH-associated LUTS. Nat Rev Urol 2011;8:8
   Google Scholar
• Itoh Y, Okada A, Yasui T, et al. Efficacy of selective alpha1A adrenoceptor antagonist silodosin in the medical expulsive therapy for ureteral stones. Int J Urol 2011;18:672-4
   PubMed Web of Science ®Google Scholar
• Curran MP. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: profile report. Drugs Aging 2011;28:843-5
   PubMed Web of Science ®Google Scholar
• Shibata K, Foglar R, Horie K, et al. KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol 1995;48:250-8
   PubMed Web of Science ®Google Scholar
• Roehrborn CG. Efficacy of alpha-adrenergic receptor blockers in the treatment of male lower urinary tract symptoms. Rev Urol 2009;11:S1-8
   PubMedGoogle Scholar
• Chapple CR, Montorsi F, Tammela TL, et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol 2011;59:342-52
   PubMed Web of Science ®Google Scholar
• Marks LS, Gittelman MC, Hill LA, et al. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009;181:2634-40
   PubMed Web of Science ®Google Scholar
• Kawabe K, Yoshida M, Homma Y; Silodosin Clinical Study G. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 2006;98:1019-24
   PubMed Web of Science ®Google Scholar
• Yu HJ, Lin AT, Yang SS, et al. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). BJU Int 2011;108:1843-8
   PubMed Web of Science ®Google Scholar
• Farthing MJ AE, Abrams SM, Haug G, et al. Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction. Postgrad Med J 1994;70:363-6
   Google Scholar
• Yokoyama T, Nasu Y, Takamoto H, et al. Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study. Int J Urol 2006;13:932-8
   PubMed Web of Science ®Google Scholar
• Tsuritani S, Okumura A, Kimura H, et al. A prospective, randomized, controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: 75 mg once daily in the evening compared to 25 mg thrice daily. Urol Int 2010;85:80-7
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Yoshikawa T, Hachiya T, et al. Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. Int J Urol 2013;20(12):1234-8
   Google Scholar
• Uckert S, Kuthe A, Jonas U, et al. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001;166:2484-90
   PubMed Web of Science ®Google Scholar
• Morelli A, Sarchielli E, Comeglio P, et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med 2011;8:2746-60
   PubMed Web of Science ®Google Scholar
• Filippi S, Morelli A, Sandner P, et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007;148:1019-29
   PubMed Web of Science ®Google Scholar
• Gacci M, Salvi M, Vignozzi L, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61:994-1003
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, McVary KT, Elion-Mboussa A, et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008;180:1228-34
   PubMed Web of Science ®Google Scholar
• Oelke M, Giuliano F, Mirone V, et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012;61:917-25
   PubMed Web of Science ®Google Scholar
• Porst H, Kim ED, Casabe AR, et al. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol 2011;60:1105-13
   PubMed Web of Science ®Google Scholar
• Egerdie RB, Auerbach S, Roehrborn CG, et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med 2012;9:271-81
   PubMed Web of Science ®Google Scholar
• Donatucci CF, Brock GB, Goldfischer ER, et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU Int 2011;107:1110-16
   PubMed Web of Science ®Google Scholar
• Bechara A, Casabe A, Rodriguez Baigorri G, et al. Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study. J Sex Med 2014;11:498-505
   Google Scholar
• Curran MP. Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction. Drugs Aging 2012;29:771-81
   Google Scholar
• Goldfischer E, Kowalczyk JJ, Clark WR, et al. Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant alpha1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial. Urology 2012;79:875-82
   Google Scholar
• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37-49
   PubMed Web of Science ®Google Scholar
• Fullhase C, Chapple C, Cornu JN, et al. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol 2013;64:228-43
   PubMed Web of Science ®Google Scholar
• Sacco E, Bientinesi R. Mirabegron: a review of recent data and its prospects in the management of overactive bladder. Ther Adv Urol 2012;4:315-24
   PubMedGoogle Scholar
• Takeda M, Obara K, Mizusawa T, et al. Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther 1999;288:1367-73
   PubMed Web of Science ®Google Scholar
• Notte SM, Marshall TS, Lee M, et al. Content validity and test-retest reliability of Patient Perception of Intensity of Urgency Scale (PPIUS) for overactive bladder. BMC Urol 2012;12:26
   Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 2013;63:283-95
   PubMed Web of Science ®Google Scholar
• Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013;189:1388-95
   PubMed Web of Science ®Google Scholar
• Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 2013;82:313-20
   PubMed Web of Science ®Google Scholar
• Nitti VW, Rosenberg S, Mitcheson DH, et al. Urodynamics and safety of the beta(3)-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol 2013;190:1320-7
   PubMed Web of Science ®Google Scholar
• Ogura K, Sengiku A, Miyazaki Y, et al. Effects of add-on mirabegron on storage symptoms in men with lower urinary tract symptoms receiving alpha-1 blocker therapy. Eur Urol Suppl 2013;12:e1091
   Google Scholar
• Malik M, van Gelderen EM, Lee JH, et al. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. Clin Pharmacol Ther 2012;92:696-706
   PubMed Web of Science ®Google Scholar
• Nitti VW, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract 2013;67:619-32
   PubMed Web of Science ®Google Scholar
• Lepor H. The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia. Rev Urol 2006;8:183-9
   PubMedGoogle Scholar
• Russo A, Castiglione F, Salonia A, et al. Effects of the gonadotropin-releasing hormone antagonist ganirelix on normal micturition and prostaglandin E(2)-induced detrusor overactivity in conscious female rats. Eur Urol 2011;59:868-74
   Google Scholar
• Debruyne F, Tzvetkov M, Altarac S, et al. Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia. Urology 2010;76:927-33
   PubMed Web of Science ®Google Scholar
• Daly DM, Collins VM, Chapple CR, et al. The afferent system and its role in lower urinary tract dysfunction. Curr Opin Urol 2011;21:268-74
   Google Scholar
• Comeglio P, Chavalmane AK, Fibbi B, et al. Human prostatic urethra expresses vitamin D receptor and responds to vitamin D receptor ligation. J Endocrinol Invest 2010;33:730-8
   Google Scholar
• Adorini L, Penna G, Amuchastegui S, et al. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem Mol Biol 2007;103:689-93
   PubMed Web of Science ®Google Scholar
• Crescioli C, Morelli A, Adorini L, et al. Human bladder as a novel target for vitamin D receptor ligands. J Clin Endocrinol Metab 2005;90:962-72
   PubMed Web of Science ®Google Scholar
• Morelli A, Vignozzi L, Filippi S, et al. BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder. Prostate 2007;67:234-47
   PubMed Web of Science ®Google Scholar
• Adorini L, Penna G, Fibbi B, et al. Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia. Ann N Y Acad Sci 2010;1193:146-52
   PubMed Web of Science ®Google Scholar
• Schroder A, Colli E, Maggi M, et al. Effects of a vitamin D(3) analogue in a rat model of bladder outlet obstruction. BJU Int 2006;98:637-42
   PubMed Web of Science ®Google Scholar
• Colli E, Rigatti P, Montorsi F, et al. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol 2006;49:82-6
   PubMed Web of Science ®Google Scholar
• Tiwari A. Elocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility. IDrugs 2009;12:381-93
   PubMed Web of Science ®Google Scholar
• Digesu GA, Hendricken C, Fernando R, et al. Do women with pure stress urinary incontinence need urodynamics? Urology 2009;74:278-81
   Web of Science ®Google Scholar
• Russo A, Hedlund P, Montorsi F. Silodosin From Bench to Bedside: selectivity, Safety, and Sustained Efficacy. Eur Urol Suppl 2011;10:445-50
   Google Scholar
• Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003;44:637-49
   PubMed Web of Science ®Google Scholar
• Rosen RC, Wei JT, Althof SE, et al. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry. Urology 2009;73:562-6
   PubMed Web of Science ®Google Scholar
• Gacci M, Eardley I, Giuliano F, et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011;60:809-25
   PubMed Web of Science ®Google Scholar
• Andersson KE, de Groat WC, McVary KT, et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn 2011;30:292-301
   PubMed Web of Science ®Google Scholar
• Giuliano F, Uckert S, Maggi M, et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol 2013;63:506-16
   PubMed Web of Science ®Google Scholar